

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Brolucizumab for treating diabetic macular oedema

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final Draft Guidance

(when no Draft Guidance was issued)

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

The committee recognised that the patient population of this appraisal is a protected group under the Equality Act of 2010. This is because visual impairment resulting from wet age-related macular degeneration is recognised as a disability.
--

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

Stakeholders mentioned that as with diabetes, there are particular ethnic groups with a higher risk of diabetic macular oedema. Diabetes is likely to affect older people and pregnant women. They also said the prevalence of diabetes varies across protected and socioeconomic characteristics. Issues related to differences in the prevalence or incidence of a disease can't be addressed by the committee in a technology appraisal.

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Section 3.6

Approved by Associate Director (name): Ross Dent

Date: 15/07/2022